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Introduction
Reward learning (RL), the ability of reward to modulate future 
behaviour, is believed to contribute to the aetiology and treatment 
of depression (Der-Avakian et al., 2015; Vrieze et al., 2013). 
Probabilistic reward learning (PLT) and probabilistic reversal 
learning tasks (PRLT) have been used to study RL and the behav-
ioural response to positive and negative feedback in humans and 
animals (Bari et al., 2010; Murphy et al., 2003; Slaney et al., 
2018). Patients with major depressive disorder (MDD) show 
increased sensitivity to misleading feedback but respond nor-
mally to accurate negative feedback (Murphy et al., 2003; Taylor 
Tavares et al., 2008). MDD patients and patients in remission 
also have an impaired ability to integrate reward information 
over time (Pechtel et al., 2013; Pizzagalli et al., 2008).
Translation of human PLTs into rodent paradigms (Bari et al., 
2010; Der-Avakian et al., 2013) provides an opportunity to probe 
the link between RL and depressive behaviour. Two types of 
tasks are commonly used: PLTs and PRLTs, the reversal learning 
version also providing a measure of cognitive flexibility. Utilising 
a PRLT, Bari et al. (2010) observed that chronic 5-mg/kg citalo-
pram treatment increased positive feedback sensitivity (PFS) 
while acutely and bidirectionally modulating reversal perfor-
mance and negative feedback sensitivity (NFS). Drozd et al. 
(2018) further characterised the PRLT with a range of conven-
tional antidepressants and observed no effects with escitalopram 
and venlafaxine treatment, although mirtazapine decreased RL 
performance. The rapid-acting antidepressant, ketamine, has also 
been investigated in the PRLT with Rychlik et al. (2017) 
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reporting decreased sensitivity to misleading negative feedback 
following treatment. Another PLT, the Response Bias 
Probabilistic Reward Task, has also been developed for rodents, 
and it has been shown to be sensitive to dopaminergic manipula-
tions whereby amphetamine enhanced but pramipexole impaired 
RL (Der-Avakian et al., 2013). Antidepressants have not yet been 
assessed in this task.
Modulation of reward-related behaviour has been relatively 
widely studied in both animal models and humans (Lewis et al., 
2019; Robinson and Roiser, 2016; Slaney et al., 2018). In tradi-
tional rodent models of anhedonia, chronic stress-induced 
impairments in reward sensitivity are reversed by chronic but not 
acute antidepressant treatments (Willner, 2017), while ketamine 
rapidly reverses these deficits (Yang et al., 2015). Recently, 
human emotional processing tasks have been translated into 
methods suitable for non-human species to study reward-related 
cognitive biases in rodent models (Hales et al., 2014; Robinson 
and Roiser, 2016). In the affective bias test (ABT), an assay prob-
ing how affective biases modulate learning and memory, conven-
tional antidepressant treatment induces a positive bias during 
learning of new substrate-reward associations but does not ame-
liorate previously learnt negative biases (Stuart et al., 2013, 
2015). Conversely, ketamine treatment was found to block nega-
tive biases but have no effect upon new learning. The judgement 
bias task (JBT) investigates how cognitive biases alter the valua-
tion of ambiguous information. Within the JBT, ketamine rapidly 
increases optimistic responses towards the ambiguous cue, while 
conventional antidepressant treatment requires 2 weeks of treat-
ment for an effect (Hales et al., 2017). Taken together, these find-
ings suggest that different underlying neuropsychological process 
contribute to reward-related behaviours, and these are differen-
tially modulated in models of depression and in response to 
delayed versus rapid-acting antidepressants.
In this study, we sought to compare the effects of conven-
tional monoaminergic antidepressants and rapid-acting antide-
pressants upon behaviour in the PRLT. We tested the conventional 
antidepressants citalopram, venlafaxine and reboxetine along-
side the rapid-acting antidepressants ketamine and scopolamine 
at doses previously used in the ABT and JBT. Drugs were 
administered acutely as our primary interest was the effects of 
the rapid-onset antidepressants upon RL. Some conventional 
antidepressants have been reported to acutely exacerbate anxiety 
(Urban et al., 2016); however, they still have acute antidepres-
sant effects (Harmer et al., 2009; Stuart et al., 2013), and acute 
dosing allows comparison with previous PRLT studies. We addi-
tionally analysed data using a Q-learning model to probe para-
meter changes underlying differences in RL performance. By 
dissociating the neuropsychological mechanisms underlying 
differential responses to conventional and rapid-acting antide-
pressant treatment, this will aid in the development of future 
antidepressant compounds with both long-lasting efficacy and a 
rapid-onset of action.
Methods
Animals and housing
Twelve male Lister-hooded rats (Harlan, UK) were housed in 
pairs within enriched laboratory cages (55 × 35 × 21 cm) contain-
ing sawdust, paper bedding, red Perspex houses (30 × 17 × 10 cm), 
cotton rope and cardboard tubes. Sample size was estimated based 
on previous studies using a similar task and manipulations (Bari 
et al., 2010). Animals weighed on average 272 g at the start of 
training and 419 g prior to the commencement of drug study 
experiments. Rats were kept in temperature-controlled conditions 
(21 ± 1°C) and under a 12:12 h reverse light–dark cycle (lights off 
at 08:00 h). Water was available ad libitum in the home cage, but 
animals were mildly food restricted to no less than 90% of their 
free-feeding weight matched to a normal growth curve (≈18 g of 
food per rat/day laboratory chow (LabDiet, PMI Nutrition 
International)). All dosing and behavioural testing was carried out 
in the animals’ active phase between 09:00 and 18:00 h. All exper-
iments were carried out in accordance with local institutional 
guidelines (University of Bristol Animal Welfare and Ethical 
Review Board), the UK Animals (Scientific procedures) Act of 
1986 and the European Parliament and Council Directive of 22 
September 2010 (2010/63/EU).
Apparatus
Behavioural testing was carried out in touchscreen operant boxes 
(Med Associates, USA) containing a magazine delivering 45-mg 
reward pellets (Test Diet, Sandown Scientific, UK), house light, 
tone generator and infrared touchscreen panel with three win-
dows within which animals could respond. The system was con-
trolled by KLimbic Software (Conclusive Solutions Ltd, UK), 
and output files were then decoded in a custom MATLAB 
(MathWorks Inc version R2017a, USA) programme (see ‘Data 
analysis and output measures’).
Behavioural task
The PRLT was adapted for use on a touchscreen operant system 
from the original design by Bari et al. (2010) (see Figure 1(a) for 
a summary of the task design).
Training. Training was conducted in three stages. In stage 1, 
animals learnt to touch an initiation square presented in the centre 
window of the screen to receive a single reward pellet for a maxi-
mum of 120 trials or 30 min (whichever was reached first). In 
common with other touchscreen operant tasks, animals typically 
responded to the screen with their noses (Horner et al., 2013). 
Once animals reached criterion (completion of all 120 trials 
within a session for two consecutive sessions, mean time to train: 
6.7 ± 0.51 sessions), they progressed onto stage 2. In this phase, 
animals had to first press the initiation square before then press-
ing either of two stimuli simultaneously presented in the left and 
right window to receive reward (max 200 trials or 40 min). Ani-
mals were deemed to reach criteria when they completed 80% of 
trials for two consecutive sessions (mean time to train: 2.25 ± 0.13 
sessions). Rats then progressed onto the main spatial probabilis-
tic reversal learning protocol.
Behavioural testing. In the PRLT, animals had to first press an 
initiation stimulus in the centre of the screen before then choosing 
to respond to either a left or right spatial stimulus. There was no 
time limit for the response to the initiation screen enabling ani-
mals to self-pace the task. Stimuli were probabilistically rewarded 
such that the ‘rich’ stimulus had an 80% chance of reward and the 
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‘lean’ stimulus had only a 20% chance of reward. Once an animal 
had selected a stimulus, they were either presented with a reward 
pellet in the magazine (once animals had retrieved the reward, the 
initiation screen illuminated and they could begin the next trial) or 
punished with no reward and a timeout of 5 s with the house light 
on. If animals did not make a choice of stimuli within 10 s after 
trial initiation, this was classified as an omission and animals 
received a timeout of 5 s during which time the house light was 
illuminated. Following eight consecutive ‘rich’ stimulus choices, 
the contingencies switched so that the spatial location previously 
associated with the ‘rich’ stimulus was now associated with the 
‘lean’ stimulus and vice versa. Animals were permitted to serially 
reverse throughout a session (max 200 trials or 40 min). The spa-
tial location of the ‘rich’ stimulus at the start of a session was 
consistent across sessions and counterbalanced across animals. 
Changing the location of the rich stimulus at the start of a session 
did not have any effect of overall task performance (see Supple-
mental Figure S2). Training was deemed to have been complete 
when animals’ performance had stabilised in the main output 
parameters of interest, allowing drug study experiments to com-
mence (no main effect of session over last five sessions of training 
in rule changes, win-stay probability, lose-shift probability and 
initiation reaction time, see Supplemental Figure S1).
Experimental design
Acute dose–response studies were conducted in a blinded, within-
subject fully counterbalanced design with all animals receiving 
every dose of drug. Treatment groups were allocated through use 
of a fully randomised design containing four treatment groups 
(except for the scopolamine study where three groups were used) 
with each group having the treatments in a different order. The 
conventional antidepressants citalopram hydrobromide (Selective 
serotonin reuptake inhibitor (SSRI), 1, 3, 10 mg/kg; t = −30 m; 
HelloBio, UK), venlafaxine hydrochloride (serotonin–noradrena-
line reuptake inhibitor (SNRI), 1, 3, 10 mg/kg; t = −30 m; HelloBio, 
UK) and reboxetine mesylate hydrate (noradrenaline reuptake 
inhibition (NRI), 0.1, 0.3, 1 mg/kg; t = −30 m; Sigma-Aldrich, 
UK) alongside the rapid-acting antidepressants ketamine hydro-
chloride (N-methyl-D-aspartate (NMDA) antagonist, 1, 3, 10 mg/
kg; t = −60 m; Sigma-Aldrich, UK) and scopolamine hydrobro-
mide (muscarinic antagonist, 0.03, 0.1 mg/kg; t = −60 m; Tocris, 
UK) were all dissolved in 0.9% saline and administered before the 
start of testing by intraperitoneal injection using a low-stress tech-
nique (Stuart and Robinson, 2015). Drug doses and pre-treatment 
times were chosen as to be clinically relevant and were based upon 
previous behavioural studies (Bari et al., 2010; Hales et al., 2017; 
Jones and Higgins, 1995; Stuart et al., 2013). All studies were car-
ried out such that a baseline session always preceded a session 
when drug was administered, there was at least 2 days between 
each drug session and all animals completed at least five baseline 
sessions (minimum one week) between the end of a drug study and 
the commencement of the next to minimise any carryover effects 
of treatment. All drug studies were carried out in food-restricted 
animals, but a test using pre-feeding was not observed to have any 
effects on the main outcomes measured in the PRLT except from 
decreasing overall motivation (see Supplemental Figure S3).
Data analysis and output measures
Parameters of interest. Output parameters were calculated to 
be consistent with previous PRLT studies (Bari et al., 2010; 
Rychlik et al., 2017). The number of rule changes and the first 
rule change trial were defined as the number of times an animal 
was able to successfully switch reward contingencies in a session 
and the trial at which an animal first achieved criterion for a rule 
change within a session, respectively. Win-stay behaviour was 
analysed as a proxy of PFS (how likely animals were to change 
their behaviour as a function of positive feedback), alongside 
lose-shift behaviour (how likely animals were to shift responding 
following negative feedback) which was examined as a proxy of 
NFS. Win-stay behaviour was defined as the probability upon 
receiving a reward at a stimulus that the rat would stay at that 
stimulus for the next trial as opposed to shifting to the opposite 
stimulus. Conversely, lose-shift behaviour was defined as the 
probability that following punishment at a stimulus, the rat would 
Figure 1. Overview of experimental protocol. (a) Schematic of 
all possible routes for a single successful trial in the PRLT task. 
Probabilities of each outcome are depicted by the width of each arrow. 
Green arrows represent an animal making an action, while white arrows 
depict transfer from one stage of a trial to the next. If no response was 
detected within 10 s of an animal pressing the initiation square, then 
this was classed as an omission and animals received a 5-s timeout. 
(b) Details of pharmacological studies, order refers to the sequence in 
which individual drug studies were carried out.
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switch to the opposite stimulus for the next trial. Win-stay and 
lose-shift behaviour were additionally subdivided into either true 
or misleading feedback based upon whether the feedback given 
matched with the underlying rule of the task at the time. For 
example, if a rat was punished for selecting the ‘rich’ stimulus, 
this would be classed as misleading feedback but if it was 
rewarded for selecting the ‘rich’ stimulus, this would match with 
the underlying rule of the task and, therefore, be true feedback. 
Initiation reaction time was defined as the time taken for rats to 
respond to the presentation of the initiation square in the central 
window of the screen and was taken as a proxy for motivation to 
complete a trial.
Statistical analysis. Data were decoded and output measures 
calculated from KLimbic output files using a custom MATLAB 
(MathWorks Inc version R2017a, USA) programme before sta-
tistical analysis was conducted using SPSS (IBM version 24, 
USA) and output graphics constructed using GraphPad Prism 7 
(GraphPad Software, USA). Sample size was calculated from 
previous experiments utilising similar behavioural tasks. Outlier 
exclusion was conducted blind to treatment, and animals that 
completed less than 50 trials were only analysed for the variables: 
number of rule changes and first rule change trial. Individual 
drug studies were analysed independently. Each behavioural 
parameter was analysed using one or two factor repeated mea-
sures analysis of variance (RM-ANOVA) with the factors treat-
ment (containing each dose as a level) or treatment and feedback 
type, respectively (for true/misleading feedback analysis). All 
data were assessed for violations of sphericity using Mauchly’s 
test and where this was the case, degrees of freedom were 
adjusted using the Huynh–Feldt correction. Post hoc analysis was 
conducted using Sidak’s correction. Where data were non-nor-
mally distributed (assessed using Kolmogorov–Smirnov and 
Shapiro–Wilk tests), output variables were evaluated using the 
Friedman test with post hoc analysis carried out using Bonfer-
roni-corrected Wilcoxon signed rank tests. Dotted lines indicate 
separate drug studies. A bracket and star(s) over multiple bars 
indicates a main effect of treatment, while star(s) over a single 
bar indicates a post hoc significant difference compared to vehicle 
treatment for that drug study. All data are shown as mean ± stan-
dard error of mean (SEM), *⩽0.05, **<0.01, ***<0.001, 
****<0.0001.
Modelling
Computational modelling of behavioural responses provides 
another method for evaluating the mechanism of antidepressant 
drug action by probing the underlying computational processes 
occurring in the brain to produce behaviour. The Q-learning model 
is one of the most widely used models for analysis of reinforce-
ment learning and works using the same input information availa-
ble to the animals to iterate through each trial and make decisions 
with the aim of maximising total reward. This computer ‘optimal 
strategy’ can then be compared with animal behaviour to allow 
estimation of both absolute RL performance and estimations of 
underlying RL parameters such as learning rate and softmax tem-
perature. Theoretical accuracy was described as how well animals’ 
performance matched up to the model-predicted perfect strategy, 
allowing an estimation of absolute RL efficiency within a session. 
This is a different measure to observed accuracy which was a 
direct measure of task performance. β (the inverse temperature of 
the softmax equation) is related to how deterministic stimulus 
choices are, with high β values meaning that choices are made 
towards stimuli with higher estimated values, while low β values 
essentially mean that choices are random (Grogan et al., 2017). 
Data from both training and each drug study were analysed using a 
Q-learning model (Watkins and Dayan, 1992) adapted from 
Grogan et al. (2017) and discussed in detail there. Briefly, for each 
trial, the value (Q) of choosing each stimulus is updated with a 
proportion of the reward prediction error (RPE) – the difference 
between the reward expected from an action and the reward 
received. The proportion of the RPE used for updating is controlled 
by the learning rate (α) parameter. For acute drug studies, data for 
each individual rat were fit to two models: one containing a single 
learning rate (Qlearn1) and another containing a dual learning rate 
for positive and negative information (Qlearn2). The choice of 
model fit for each animal was made using Bayesian information 
criteria (BIC; Schwarz, 1978) when fitted to the vehicle data, with 
the model with the lowest BIC chosen. For every drug study, the 
single learning rate model (Qlearn1) was the better fitting model 
(Supplemental Figure S4). Once the model had been fit, these 
starting parameters were used to individually fit each dose and ani-
mal separately to create the output parameters.
Results
Effects of conventional antidepressants
Reboxetine decreased the number of rule changes (Figure 2(a)) 
within a session (RM-ANOVA, F3,30 = 3.31, p = 0.033), an overall 
integrative measure of RL performance. Although there was no main 
effect of citalopram treatment upon rule changes, there was a ten-
dency for higher rule change performance when the first two doses 
of citalopram plus vehicle were analysed in isolation (RM-ANOVA, 
F2,22 = 2.91, p = 0.076). Citalopram reduced the trials taken to reach 
the first rule change (Friedman test, χ2(3) = 8.50, p = 0.037, Figure 
2(b)), while there was also a trend towards reboxetine increasing the 
trials taken to reach the first rule change (Friedman test, χ2(3) = 7.02, 
p = 0.071). PFS, as measured by the proportion of win-stay behav-
iour (Figure 2(c)), was increased by citalopram treatment 
(RM-ANOVA, F3,33 = 3.81, p = 0.019). Surprisingly for an antide-
pressant, reboxetine decreased win-stay behaviour (RM-ANOVA, 
F3,24 = 6.16, p = 0.003). None of the conventional antidepressants 
tested had any effects upon lose-shift behaviour (Figure 2(d)), a 
measure of NFS. Both citalopram (RM-ANOVA, F3,33 = 8.02, 
p = 0.0004) and reboxetine (RM-ANOVA, F1.25, 12.48 = 11.17, 
p = 0.004) reduced motivation in the PRLT, as measured by the time 
taken to initiate a trial in the PRLT (Figure 2(e)). Venlafaxine (one 
animal excluded from study due to illness) had no effects on any 
variable measured in the PRLT. Reboxetine but not citalopram or 
venlafaxine also reduced the number of trials completed in a session 
(Friedman test, χ2(3) = 18.0, p = 0.0004, Supplemental Figure S5)
Effects of rapid-acting antidepressants
Both ketamine (RM-ANOVA, F3,33 = 5.697, p = 0.003) and sco-
polamine (RM-ANOVA, F2,22 = 16.23, p < 0.0001) reduced RL 
performance as measured by the number of rule changes com-
pleted in a session (Figure 3(a)). Neither drugs had any effect on 
the trial at which the first rule change was achieved (Figure 3(b)); 
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however, both ketamine (RM-ANOVA, F1.97, 19.66 = 3.928, 
p = 0.037) and scopolamine (RM-ANOVA, F2,14 = 8.36, p = 0.004) 
decreased win-stay behaviour (Figure 3(c)). As seen with the con-
ventional antidepressants, neither rapid-acting antidepressant 
tested had any effect on lose-shift behaviour (Figure 3(d)). 
Consistent with citalopram and reboxetine, both ketamine 
(RM-ANOVA, F1.08, 9.68 = 7.36, p = 0.021) and scopolamine 
(Friedman test, χ2(2) = 7.75, p = 0.021) also decreased motivation 
as measured by the time taken to initiate a trial (Figure 3(e)). Both 
ketamine (Friedman test, χ2(3) = 19.08, p = 0.0003, Supplemental 
Figure S5) and scopolamine (Friedman test, χ2(2) = 14.6, 
p = 0.0007, Supplemental Figure S5) additionally reduced trials 
completed by animals within a session.
Effects of antidepressant treatment on true 
or misleading feedback
Recent evidence has suggested that pharmacological treatment 
can differentially effect the way animals respond to probabilistic 
rewards depending on whether they agree or disagree with the 
animals’ expectation of task feedback (Drozd et al., 2018; Rychlik 
et al., 2017). This has been described corresponding to either true 
or misleading feedback. We, therefore, re-analysed win-stay and 
lose-shift data to observe if acute antidepressant treatment in the 
PRLT differentially effects responses to the different feedback 
types. There was an inconsistent response to feedback type 
between experiments with the only difference found for the win-
stay responses between true and misleading positive feedback for 
the venlafaxine study (two-way ANOVA, F1,10 = 8.00, p = 0.018, 
Figure 4(c)). There was a more consistent difference in lose-shift 
probability between true and misleading negative feedback 
with venlafaxine (two-way ANOVA, F1,10 = 32.72, p = 0.0002, 
Figure 4(d)), reboxetine (two-way ANOVA, F1,10 = 19.81, 
p = 0.001, Figure 4(f)) and ketamine studies (two-way ANOVA, 
F1,9 = 8.72, p = 0.016, Figure 4(h)) showing a decreased lose-shift 
probability following misleading feedback compared to true 
feedback. An interaction between ketamine treatment and feed-
back type was also observed for animal’s lose-shift response to 
true and misleading feedback (two-way ANOVA, F3,27 = 3.565, 
p = 0.027, Figure 4(h)). Further analysis revealed no effect of 
ketamine treatment on true lose-shift behaviour but a trend 
towards decreased sensitivity to NFS following misleading feed-
back emerged (RM-ANOVA, F3,27 = 2.69, p = 0.066). Across all 
Figure 2. Effects of delayed antidepressant administration in the PRLT. (a) Rule changes completed within a session. (b) Trial at which animals first 
met the criterion for a rule change. (c) Win-stay probability. (d) Lose-shift probability. (e) Initiation reaction time. Dotted lines indicate separate 
drug studies.
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studies, no main effects of drug treatment were observed, 
although trends were observed towards decreased win-stay 
behaviour following reboxetine (two-way ANOVA, F3,30 = 2.67, 
p = 0.066, Figure 4(e)) and scopolamine (two-way ANOVA, 
F2,14 = 3.17, p = 0.073, Figure 4(i)) treatment alongside a trend 
towards decreased lose-shift behaviour following citalopram 
treatment (two-way ANOVA, F3,33 = 2.62, p = 0.067, Figure 4(b)).
Q-learn modelling of antidepressant 
treatment in the PRLT
The Q-learning model was first used to analyse training data 
where the parameter learning rate followed the same relationship 
as the behavioural outcome rule changes, a measure of overall 
RL performance (Figure 5(a)). Theoretical accuracy, the accu-
racy of animals compared to a model-predicted optimal strategy, 
also followed a close relationship with the overall accuracy of 
animals in the task (Figure 5(b)), with animals always following 
a close but non-optimal strategy compared to ideal.
Acute dose–response study data was analysed using the Qlearn1 
model due to it being the better fitting model. Both reboxetine 
(RM-ANOVA, F3,30 = 3.14, p = 0.04, Figure 5(c)) and scopolamine 
(RM-ANOVA, F1.247,8.728 = 8.77, p = 0.013) decreased theoretical 
accuracy, the degree to which rats’ behaviour deviated from an opti-
mal choice strategy. Ketamine (RM-ANOVA, F1.31, 13.10 = 7.41, 
p = 0.013, Figure 5(d)) and scopolamine (RM-ANOVA, F2,14 = 12.36, 
p = 0.0008) both decreased the learning rate, the degree to which 
new evidence is used to make decisions as opposed to previously 
stored information. Softmax β, a measure of how deterministic ani-
mals’ stimulus choices are, was increased by citalopram treatment 
(RM-ANOVA, F3,33 = 7.24, p = 0.0007, Figure 5(e)). Conversely, 
stimulus selection was more random (lower β) when animals were 
treated with reboxetine (RM-ANOVA, F3,30 = 4.13, p = 0.014).
Discussion
Conventional antidepressants
Citalopram was the only conventional antidepressant tested 
exhibiting behavioural effects consistent with its antidepres-
sant role. Treated animals required fewer trials to learn the first 
probabilistic rule, exhibited increased PFS and deterministic 
Figure 3. Effects of rapid-onset antidepressant administration in the PRLT. (a) Rule changes completed within a session. (b) Trial at which animals 
first met the criterion for a rule change. (c) Win-stay probability. (d) Lose-shift probability. (e) Initiation reaction time. Dotted lines indicate 
separate drug studies.
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Figure 4. Effects of antidepressant treatment upon true versus misleading feedback sensitivity. Responses were divided as to whether they met 
the underlying rule of the task (true feedback) or clashed with the underlying rule (misleading feedback) the animal was required to learn at the 
time. (a) Citalopram: Win-stay probability. (b) Citalopram: Lose-shift probability. (c) Venlafaxine: Win-stay probability. (d) Venlafaxine: Lose-shift 
probability. (e) Reboxetine: Win-stay probability. (f) Reboxetine: Lose-shift probability. (g) Ketamine: Win-stay probability. (h) Ketamine: Lose-shift 
probability. (i) Scopolamine: Win-stay probability. (j) Scopolamine: Lose-shift probability. A bracket and star(s) over multiple bars indicates a main 
effect of treatment within a feedback type (e.g. misleading lose-shift) for a single drug study. This was only assessed when a significant interaction 
between treatment and feedback type was observed in the two-way ANOVA for both feedback types combined.
8 Brain and Neuroscience Advances
Figure 5. Reinforcement learning modelling of PRLT behaviour. (a) Correlation between rule changes and model-free learning rate over the first 18 
sessions of training in the PRLT. (b) Correlation between absolute accuracy and accuracy compared to a model-predicted perfect strategy in the first 
18 sessions of training. (c) Theoretical accuracy. (d) Model-free learning rate. (e) β, the inverse softmax temperature.
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stimulus selection but did not show any increase in rule 
changes. This lack of effect upon rule changes matches escit-
alopram data from Drozd et al. (2018) who found no effect 
upon any parameter measured. However, Bari et al. (2010) 
observed that acute 5-mg/kg citalopram administration 
increased rule changes and decreased NFS, while 10-mg/kg 
chronic administration also increased PFS. Differences in 
results between the current study, Drozd et al. (2018) and Bari 
et al. (2010) may be related to animals’ level of performance 
prior to drug study experiments, with animals in this study and 
Drozd et al. (2018) performing roughly triple the baseline rule 
changes compared to Bari et al. (2010).
Reboxetine decreased RL performance and PFS. Noradrenaline 
has been observed to support choice variability with clonidine-
treated monkeys, a manipulation reducing central nervous system 
(CNS) noradrenaline levels, displaying decreased choice variabil-
ity in a sequential cost/benefit decision-making task (Jahn et al., 
2018). Reboxetine-treated animals in the present study had a 
decreased β parameter value, a proxy of increased choice variabil-
ity. In the PRLT too high a choice variability could impair the 
ability of animals to persevere at a stimulus for long enough to 
reverse (Delgado et al., 2011). However, in a fixed reward proba-
bility reversal learning task, rats administered with the NET-
biased tricyclic antidepressant (TCA) desipramine showed 
increased reversal learning performance (Seu and Jentsch, 2009). 
Potentially, increased noradrenaline is detrimental to performance 
where rules are uncertain but beneficial when the reward contin-
gencies are deterministic.
Concurrent with results from Drozd et al. (2018), acute venla-
faxine treatment did not change RL or feedback sensitivity. The 
lack of effect observed in the present study may be because of the 
mixed serotonergic and noradrenergic transporter affinities of the 
drug whereby an RL impairment caused by enhanced noradrener-
gic transmission is balanced by increased serotonergic signalling 
improving RL ability.
In the ABT, citalopram, venlafaxine and reboxetine all posi-
tively bias the valuation of reward during new learning over mul-
tiple days (Stuart et al., 2013). However, unless they are dosed 
chronically, acute conventional antidepressants do not positively 
bias the interpretation of an ambiguous cue in the JBT (Hales 
et al., 2017). These results combined with the observations in the 
present study suggest that conventional antidepressants do not 
alter absolute RL, rather requiring at least overnight integration 
of memories to have an effect.
Rapid-acting antidepressants
Both ketamine and scopolamine impaired RL, PFS and motiva-
tion. Both drugs have sedative effects at higher doses, a potential 
cause of their motivational impairments, although it has been 
observed that motivation and RL are dissociable within the PRLT 
(Roberts et al., 2019). Rychlik et al. (2017) argued that attenuat-
ing animals’ sensitivity to misleading negative feedback may be 
a mechanism for ketamine’s therapeutic action. We also observed 
an interaction between ketamine treatment and feedback type 
with a trend towards decreased misleading NFS. However, inter-
preting the significance of this finding is difficult when compared 
with the marked impairments ketamine had upon overall proba-
bilistic learning and PFS. No such interaction was seen in ani-
mals treated with scopolamine.
Other studies have also suggested ketamine impairs reward 
processing. Administration of ketamine to both rats (10 mg/kg) 
and humans (0.5 mg/kg) has been found to reduce reward antici-
pation responses in the ventral striatum to either money or food 
(Francois et al., 2016). In addition, it has been observed that keta-
mine (32 mg/kg) impairs rats’ ability to assign a motivational 
value to a reward-predicting cue (Fitzpatrick and Morrow, 2017). 
Scopolamine’s ability to impair RL has been observed in other 
tasks, with an acute 0.17-mg/kg dose increasing error rate upon 
rule reversal in a non-probabilistic reversal learning task in mice 
(Pelsőczi and Lévay, 2017).
In similar low doses to those tested here, work in our labora-
tory has previously observed that ketamine has a robust effect on 
ambiguous cue interpretation and retrieval of memory biases in 
the ABT at 1 mg/kg (Hales et al., 2017; Stuart et al., 2015). These 
results combined with observations from the present study seem 
to suggest that while ketamine administration impairs RL, in 
assays of affective bias, it modifies biases during retrieval and 
positively biases interpretation of ambiguous cues. With regard 
to scopolamine, one could tentatively conclude that scopolamine 
appears to impair RL; however, more research is needed.
Reinforcement learning model
When fitting behavioural data with the Q-learn model, we 
observed that the single learning rate Q-learning model fits best, 
irrespective of drug treatment. This is in contrast to previous 
PRLT studies in rodents where a dual learning rate model was the 
best fitting (Alsiö et al., 2019; Noworyta-Sokolowska et al., 
2019). This also differs to human data where a dual rate model is 
again better fitted (Grogan et al., 2017). One possibility for the 
difference in best fitting model might be due to subtleties in the 
training for the task resulting in animals within different studies 
using different strategies to perform the task. The fact that theo-
retical accuracy was consistently higher than actual task accuracy 
suggests that there are factors underlying animal performance 
that are not accounted for in the Q-learning model tested here. 
Potential solutions to this could include utilising other models 
such as those employing choice stickiness (Alsiö et al., 2019) or 
fictitious updating of the non-chosen option (Noworyta-
Sokolowska et al., 2019).
Citalopram increased the β parameter, implying choices were 
more deterministic, while reboxetine led to animals making more 
random choices. Citalopram’s ability to increase deterministic 
choice selection is interesting in the context of citalopram acutely 
increasing anxiety (Urban et al., 2016) and suggests that animals 
were better able to form and execute strategy to perform the task. 
Reboxetine and scopolamine both impaired theoretical accuracy, 
while reboxetine also decreased the β parameter; these impair-
ments are consistent with their effects upon rule changes. 
Ketamine and scopolamine decreased the learning rate with this 
effect again mapping onto their impairments upon rule change 
performance. One recent study found that ketamine administra-
tion in humans performing a PRLT containing a risk-based ele-
ment caused no change in the learning rate but impaired ability to 
follow an optimal reward strategy (similar to theoretical accu-
racy, Vinckier et al., 2016). Surprisingly, it has been observed 
that learning rate is negatively correlated with reward sensitivity 
and that patients with MDD or high anhedonia have decreased 
reward sensitivity but no change in the learning rate (Huys et al., 
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2013). This would suggest that for drugs to have antidepressant 
efficacy, they cannot increase both the learning rate and reward 
sensitivity. This would mean that the ketamine-mediated decrease 
in both the learning rate and PFS is more likely due to a general 
impairment of cognitive functioning as opposed to a specific 
effect on RL.
Comparison with human literature
Human PRLT studies have observed that escitalopram and citalo-
pram increase both errors made to criterion while achieving the 
first reversal and misleading NFS (Chamberlain et al., 2006; 
Skandali et al., 2018). Tryptophan supplementation, a manipula-
tion increasing synaptic serotonin levels, has been also found to 
have no effect upon reversal learning errors in the PRLT 
(Thirkettle et al., 2019). Interestingly, the SSRI paroxetine has 
been found to attenuate the bias that depressed patients have 
towards preferentially learning from negative feedback com-
pared to positive feedback (Moustafa et al., 2013). Atomoxetine, 
a noradrenaline reuptake inhibitor, has also been observed in the 
human PRLT to have little effect on both misleading negative 
feedback and errors to criterion (Chamberlain et al., 2006; a simi-
lar measure to trials to first rule change), similar to the results 
seen in rodents. There is a lack of human studies examining any 
of the other drugs tested in the present study.
Although the translatability of the PRLT is one of its key 
strengths, there are noticeable differences between how humans 
and rodents complete the task. Aside from the previously dis-
cussed differences in model fitting between species, there are 
also marked differences in baseline feedback sensitivity. In 
response to misleading negative feedback, humans rarely switch 
to the opposite stimulus (p(lose-switch) = 0.05, Skandali et al., 
2018) compared to rats in this study (p(lose-switch) ≈ 0.65). 
Humans are also able to dissociate between true and misleading 
positive feedback (win-stay following misleading positive feed-
back: p(win-stay) = 0.01 and true positive feedback: p(win-
stay) = 0.86), while rodents in this study were not able to do this. 
This implies that rodents and humans are potentially using differ-
ent strategies to complete the task, meaning interpretation of the 
results between species might not be straightforward.
Summary
These data suggest that within this PRLT, antidepressant treat-
ment does not consistently modify RL or feedback sensitivity in 
a manner congruent with the drugs’ antidepressant efficacy or 
time course of effects. Citalopram’s ability to improve RL and 
modify PFS in the face of other drugs causing general impair-
ments suggests that the task is potentially sensitive to manipula-
tions of serotonergic neurotransmission. These results also add 
further weight that motivation and RL are dissociable within the 
PRLT due to the ability of citalopram to improve RL but impair 
motivation. Unlike tasks which measure affective biases, this 
PRLT did not reveal any differences between the rapid-acting and 
conventional antidepressants which could be related to the tem-
poral differences in their clinical benefits. Evidence from rein-
forcement learning model analysis also suggested that none of 
the drugs improved innate reward processing parameters. All the 
drugs tested are effective antidepressants but, except for citalo-
pram, either caused general impairments in RL or had no effect in 
this task. This suggests that modulation of RL and feedback sen-
sitivity, as measured in this task, does not appear to be a key 
mechanism for their therapeutic efficacy.
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